Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib.

Michael D KappelmanMillie D LongXian ZhangFeng-Chang LinLaura WeisbeinWenli ChenJessica BurrisJennifer E DorandLauren E ParlettTara FehlmannColleen M BrensingerKevin HaynesVinit NairAlan F KaulAngela DobesJames D Lewis

Published in: Crohn's & colitis 360 (2023)

Among anti-TNF experienced patients with UC, Pain Interference 4-10 months after treatment initiation was lower among tofacitinib users as compared with vedolizumab users. Many, but not all, secondary endpoints and subanalyses also favored tofacitinib. Future studies with larger sample sizes are needed to further evaluate these findings.

Keyphrases

ulcerative colitis
patient reported outcomes
rheumatoid arthritis
chronic pain
neuropathic pain